BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 27342857)

  • 1. Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer.
    Liu Y; Gunda V; Zhu X; Xu X; Wu J; Askhatova D; Farokhzad OC; Parangi S; Shi J
    Proc Natl Acad Sci U S A; 2016 Jul; 113(28):7750-5. PubMed ID: 27342857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer.
    Zhou M; Chen Y; Adachi M; Wen X; Erwin B; Mawlawi O; Lai SY; Li C
    Biomaterials; 2015 Jul; 57():41-9. PubMed ID: 25913249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sequential targeting nanoplatform for anaplastic thyroid carcinoma theranostics.
    Wang Q; Sui G; Wu X; Teng D; Zhu L; Guan S; Ran H; Wang Z; Wang H
    Acta Biomater; 2020 Jan; 102():367-383. PubMed ID: 31778831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theranostic poly(lactic-co-glycolic acid) nanoparticle for magnetic resonance/infrared fluorescence bimodal imaging and efficient siRNA delivery to macrophages and its evaluation in a kidney injury model.
    Yang C; Vu-Quang H; Husum DMU; Tingskov SJ; Vinding MS; Nielsen T; Song P; Nielsen NC; Nørregaard R; Kjems J
    Nanomedicine; 2017 Nov; 13(8):2451-2462. PubMed ID: 28842376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Tumor-Activatable Theranostic Nanomedicine Platform for NIR Fluorescence-Guided Surgery and Combinatorial Phototherapy.
    Li X; Schumann C; Albarqi HA; Lee CJ; Alani AWG; Bracha S; Milovancev M; Taratula O; Taratula O
    Theranostics; 2018; 8(3):767-784. PubMed ID: 29344305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo.
    Zhang K; Yu M; Hao F; Dong A; Chen D
    Cancer Biomark; 2016 Sep; 17(3):281-291. PubMed ID: 27802204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticle-enabled, image-guided treatment planning of target specific RNAi therapeutics in an orthotopic prostate cancer model.
    Lin Q; Jin CS; Huang H; Ding L; Zhang Z; Chen J; Zheng G
    Small; 2014 Aug; 10(15):3072-82. PubMed ID: 24706435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copper sulfide nanoparticle-based localized drug delivery system as an effective cancer synergistic treatment and theranostic platform.
    Hou L; Shan X; Hao L; Feng Q; Zhang Z
    Acta Biomater; 2017 May; 54():307-320. PubMed ID: 28274767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAG3 down-modulation reduces anaplastic thyroid tumor growth by enhancing proteasome-mediated degradation of BRAF protein.
    Chiappetta G; Basile A; Arra C; Califano D; Pasquinelli R; Barbieri A; De Simone V; Rea D; Giudice A; Pezzullo L; De Laurenzi V; Botti G; Losito S; Conforti D; Turco MC
    J Clin Endocrinol Metab; 2012 Jan; 97(1):E115-20. PubMed ID: 22072743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles.
    Satpathy M; Wang L; Zielinski RJ; Qian W; Wang YA; Mohs AM; Kairdolf BA; Ji X; Capala J; Lipowska M; Nie S; Mao H; Yang L
    Theranostics; 2019; 9(3):778-795. PubMed ID: 30809308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detecting Immune Response to Therapies Targeting PDL1 and BRAF by Using Ferumoxytol MRI and Macrin in Anaplastic Thyroid Cancer.
    Ng TSC; Gunda V; Li R; Prytyskach M; Iwamoto Y; Kohler RH; Parangi S; Weissleder R; Miller MA
    Radiology; 2021 Jan; 298(1):123-132. PubMed ID: 33107799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors.
    Min IM; Shevlin E; Vedvyas Y; Zaman M; Wyrwas B; Scognamiglio T; Moore MD; Wang W; Park S; Park S; Panjwani S; Gray KD; Tassler AB; Zarnegar R; Fahey TJ; Jin MM
    Clin Cancer Res; 2017 Dec; 23(24):7569-7583. PubMed ID: 29025766
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy.
    Xu X; Saw PE; Tao W; Li Y; Ji X; Yu M; Mahmoudi M; Rasmussen J; Ayyash D; Zhou Y; Farokhzad OC; Shi J
    Nano Lett; 2017 Jul; 17(7):4427-4435. PubMed ID: 28636389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer.
    Zhou H; Qian W; Uckun FM; Wang L; Wang YA; Chen H; Kooby D; Yu Q; Lipowska M; Staley CA; Mao H; Yang L
    ACS Nano; 2015 Aug; 9(8):7976-91. PubMed ID: 26242412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendrimer-Stabilized Gold Nanostars as a Multifunctional Theranostic Nanoplatform for CT Imaging, Photothermal Therapy, and Gene Silencing of Tumors.
    Wei P; Chen J; Hu Y; Li X; Wang H; Shen M; Shi X
    Adv Healthc Mater; 2016 Dec; 5(24):3203-3213. PubMed ID: 27901317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendrimer-encapsulated naphthalocyanine as a single agent-based theranostic nanoplatform for near-infrared fluorescence imaging and combinatorial anticancer phototherapy.
    Taratula O; Schumann C; Duong T; Taylor KL; Taratula O
    Nanoscale; 2015 Mar; 7(9):3888-902. PubMed ID: 25422147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Penetrating Theranostic Nanoparticles for Enhancement of Targeted and Image-guided Drug Delivery into Peritoneal Tumors following Intraperitoneal Delivery.
    Gao N; Bozeman EN; Qian W; Wang L; Chen H; Lipowska M; Staley CA; Wang YA; Mao H; Yang L
    Theranostics; 2017; 7(6):1689-1704. PubMed ID: 28529645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo.
    Lee SJ; Yook S; Yhee JY; Yoon HY; Kim MG; Ku SH; Kim SH; Park JH; Jeong JH; Kwon IC; Lee S; Lee H; Kim K
    J Control Release; 2015 Dec; 220(Pt B):631-41. PubMed ID: 26307351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.
    Saini S; Sripada L; Tulla K; Qiao G; Kunda N; Maker AV; Prabhakar BS
    Endocr Relat Cancer; 2019 Jun; 26(6):551-563. PubMed ID: 30999276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low intensity focused ultrasound (LIFU) triggered drug release from cetuximab-conjugated phase-changeable nanoparticles for precision theranostics against anaplastic thyroid carcinoma.
    Wang Y; Sui G; Teng D; Wang Q; Qu J; Zhu L; Ran H; Wang Z; Jin C; Wang H
    Biomater Sci; 2018 Dec; 7(1):196-210. PubMed ID: 30422139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.